INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 141 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $9,208,753 | +445.0% | 134,454 | +450.6% | 0.06% | +436.4% |
Q1 2024 | $1,689,725 | -85.8% | 24,418 | -85.3% | 0.01% | -86.1% |
Q4 2023 | $11,897,586 | +696.9% | 166,121 | +418.0% | 0.08% | +558.3% |
Q3 2022 | $1,493,000 | -58.6% | 32,071 | -49.3% | 0.01% | -65.7% |
Q2 2022 | $3,608,000 | -39.8% | 63,201 | -35.5% | 0.04% | -35.2% |
Q1 2022 | $5,992,000 | +427.0% | 97,925 | +351.0% | 0.05% | +440.0% |
Q4 2021 | $1,137,000 | -45.4% | 21,715 | -83.5% | 0.01% | -94.7% |
Q3 2017 | $2,083,000 | +313.3% | 131,980 | +325.9% | 0.19% | +272.5% |
Q1 2017 | $504,000 | +9.6% | 30,989 | +161.0% | 0.05% | -50.5% |
Q2 2016 | $460,000 | – | 11,871 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |